Search

Displaying results 1851 - 1860 of 10000 in total
  1. Drug

    Bordetella pertussis pertactin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10992
    ApprovedInvestigational

    Mixtures: Repevax Injektionssuspension in einer Fertigspritze
  2. Drug

    Omega-3-acid ethyl esters

    go.drugbank.com/drugs/DB09539
    ApprovedInvestigational

    Omega-3-acid ethyl esters are currently marketed in the US, EU, and many other regions under the brand name Lovaza[FDA Label][L5849]. … Omega-3-acid ethyl esters are prescription drugs that contain eicosapentaenoic acid-ethyl ester (EPA) and docosahexaenoic acid-ethyl ester (DHA) that are used in combination with changes in diet to lower

    Mixtures: ROSUVASTATINA E OMEGA 3 SPA SOCIET PRODOTTI ANTIBIOTICI, ROSUVASTATINA E OMEGA 3 SPA SOCIET PRODOTTI ANTIBIOTICI
  3. Drug

    Tividenofusp alfa

    go.drugbank.com/drugs/DB17628
    ApprovedInvestigational

    Developed by Denali Therapeutics, tividenofusp alfa received FDA approval on March 25, 2026, under the accelerated approval pathway [L56097, L56099]. … Tividenofusp alfa is a first-in-class, brain-penetrant enzyme replacement therapy (ERT) indicated for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome [L56097, L56099

    Synonyms: - L-iduronate sulfate sulfatase, EC:3.1.6.13) pro-protein (1-525), fused via the peptide linker 526 GGGGS 530 to a human immunoglobulin G1 C-terminal Fc fragment (531-757) variant (L 544>A, L 545>A, T
  4. Drug

    Carisoprodol

    go.drugbank.com/drugs/DB00395
    Approved

    This drug is available by itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with both aspirin and codeine [FDA label, F4060, F4069]. … Originally approved by the FDA in 1959 [FDA label], carisoprodol is a centrally acting muscle relaxant used in painful musculoskeletal conditions in conjunction with physical therapy and other medications

    Synonyms: N-isopropy-2-methyl-2-propyl-1,3-propanediol dicarbamate
  5. Drug

    Romosozumab

    go.drugbank.com/drugs/DB11866
    ApprovedInvestigational

    Romosozumab was granted FDA approval on April 9,2019[L5921]. … Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant

    Products: EVENITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 105 MG/1.17 ML, EVENITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 105MG/1.17ML
  6. Drug

    Flurandrenolide

    go.drugbank.com/drugs/DB00846
    Approved

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p733) … A corticosteroid used topically in the treatment of various skin disorders. It is usually employed as a cream or an ointment, and is also used as a polyethylene tape with an adhesive.

  7. Drug

    Dicoumarol

    go.drugbank.com/drugs/DB00266
    Approved

    In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases. … Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K.

  8. Drug

    Janssen COVID-19 Vaccine

    go.drugbank.com/drugs/DB15857
    ApprovedInvestigational

    The Janssen COVID-19 vaccine is available under an Emergency Use Authorization (EUA) in the US.[L41745] … Follow-up preclinical studies in rhesus monkeys[A220058] showed that the Ad26 vaccine produced a robust response and provided near perfect protection in nasal swabs and bronchoalveolar lavage following

  9. Drug

    Bendazac

    go.drugbank.com/drugs/DB13501
    ApprovedWithdrawn

    Bendazac is an oxyacetic acid [A39863, A39869]. … the denaturation of proteins - an effect that has primarily proven useful in managing and delaying the progression of ocular cataracts [A39863.

  10. Drug

    Erdafitinib

    go.drugbank.com/drugs/DB12147
    ApprovedInvestigational

    [L5956, L5959] Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic … In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for